3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
2
Recurrence
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
27
pembrolizumab
26
Cisplatin
24
Paclitaxel
21
Nivolumab
19
Gemcitabine
16
Pemetrexed
14
Rituximab
14
Ipilimumab
12
Cyclophosphamide
11
Dexamethasone
11
Fluorouracil
10
Capecitabine
9
Docetaxel
9
durvalumab
9
trastuzumab deruxtecan
9
Lenalidomide
8
Oxaliplatin
8
atezolizumab
8
Doxorubicin
7
daratumumab
7
osimertinib
7
Bortezomib
6
Cytarabine
6
Leucovorin
6
Trastuzumab
6
olaparib
6
venetoclax
6
130-nm albumin-bound paclitaxel
5
Ado-Trastuzumab Emtansine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
dostarlimab
×
1 year
×
Clear all
NCT02715284
2026-01-13
GARNET
Tesaro, Inc.
Phase 1
Active not recruiting
730 enrolled
3 FDA
NCT03981796
2025-09-03
RUBY
Tesaro, Inc.
Phase 3
Active not recruiting
785 enrolled
2 FDA